Dade Behring, University of Frankfurt and Innovectis Announce Exclusive License and Research Agreements for Cardiac Markers.DEERFIELD, Ill. & FRANKFURT, Germany -- Complementary markers for Dade Behring's portfolio for the diagnosis of acute coronary syndrome acute coronary syndrome n. A sudden, severe coronary event that mimics a heart attack, such as unstable angina. acute coronary syndrome Dade Behring (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :DADE), the University of Frankfurt University of Frankfurt may refer to two (or three) German universities:
The agreement provides the basis for joint efforts of Innovectis, the University of Frankfurt, and Dade Behring to establish these and potentially future markers of vascular diseases vascular diseases, n.pl diseases of the peripheral circulatory system. as routine diagnostic tests, and thus provide physicians with valuable information on the prognosis and adequate treatment of a potential cardiac event cardiac event Coronary event Cardiology Any severe or acute cardiovascular condition including acute MI, unstable angina, or cardiac mortality in healthy persons (primary risk assessment) and for patients with ACS (secondary risk assessment). "Cardiovascular diseases are the world's number one health threat. With these agreements Dade Behring confirms once again its sincere dedication to developing blood tests that substantially enhance diagnosis and which can lead toward more successful patient management," said Jim Reid-Anderson, Chairman, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , Dade Behring. "We are most pleased with this development, since the acquisition of these new markers synergistically syn·er·gis·tic adj. 1. Of or relating to synergy: a synergistic effect. 2. Producing or capable of producing synergy: synergistic drugs. 3. complements our strong portfolio in the diagnostic area of cardiac diseases, an area in which Dade Behring is a worldwide market leader." About the role of the emerging markers in ACS ACS describes the continuum from unstable angina to myocardial infarction. For the successful and efficient management of this health threat, an early and accurate diagnosis of patients is a prerequisite, which helps physicians provide the patient with an optimal treatment. The emerging markers PlGF and sCD40L have been shown in studies to provide valuable information for the diagnosis of ACS. Originally identified in the placenta, PlGF is now considered to be a cardiovascular disease marker and a primary instigator in·sti·gate tr.v. in·sti·gat·ed, in·sti·gat·ing, in·sti·gates 1. To urge on; goad. 2. To stir up; foment. [Latin of atherosclerotic plaque instability. Apart from its potential as a marker for cardiovascular disease in general, it has been recognized as an independent and powerful predictor for adverse outcome for patients with known or suspected ACS(2). Until recently, sCD40L has only been proposed as a primary risk assessment marker. It has also been proposed for the identification of patients who benefit from glycoprotein IIb/IIIa receptor antagonist ReoPro(R) (abciximab) therapy. Now, recent studies of Prof. Zeiher's group have shown that sCD40L is also an independent secondary risk assessment marker for ACS(3). PlGF and sCD40L provide independent complementary information to routine markers such as cardiac troponins and CardioPhase hsCRP(R), among others. About Innovectis Innovectis was founded in the year 2000 as an innovation service provider of the University of Frankfurt. It offers research and development services as well as task analysis and markets trademark rights of the University of Frankfurt, the TU Darmstadt (Technical University) and the FH Darmstadt (University of Applied Sciences). Further information is available at www.innovectis.de. About Dade Behring With 2003 revenues of more than $1.4 billion, Dade Behring (NASDAQ:DADE) is the world's largest company dedicated solely to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of labs, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the Internet at www.dadebehring.com. 1. Baldus, S., C. Heeschen, et al. (2003). "Myeloperoxidase Serum Levels Predict Risk in Patients With Acute Coronary Syndromes." Circulation. 2. Heeschen, C., S. Dimmeler, et al. (2004). "Prognostic value of placental growth factor in patients with acute chest pain." JAMA JAMA abbr. Journal of the American Medical Association 291(4): 435-41. 3. Heeschen, C., S. Dimmeler, et al. (2003). "Soluble CD40 ligand in acute coronary syndromes." N Engl J Med 348(12): 1104-11. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion